Literature DB >> 20696662

Polymorphisms at the Microseminoprotein-beta locus associated with physiologic variation in beta-microseminoprotein and prostate-specific antigen levels.

Xing Xu1, Camilla Valtonen-André, Charlotta Sävblom, Christer Halldén, Hans Lilja, Robert J Klein.   

Abstract

BACKGROUND: rs10993994, a single nucleotide polymorphism (SNP) at the genetic locus encoding beta-microseminoprotein (beta-MSP), is associated with both prostate cancer risk and levels of blood prostate-specific antigen (PSA), a biomarker used in prostate cancer screening. Therefore, we wished to determine the association between SNPs at MSMB, the gene encoding beta-MSP, and the levels of prostate-produced biomarkers beta-MSP, PSA, and human kallikrein 2 (hK2) in blood and semen.
METHODS: Blood and semen from 304 healthy young Swedish men (ages 18-21) were assayed for beta-MSP, PSA, and hK2. SNPs around MSMB were genotyped from matched DNA and analyzed for quantitative association with biomarker levels. Empirical P values were multiple test-corrected and the independence of each SNP's effect was determined.
RESULTS: rs10993994 was significantly associated with the blood and semen levels of beta-MSP (both P < 1.0 x 10(-7)) and PSA (P = 0.00014 and P = 0.0019), and semen levels of hK2 (P = 0.00027). Additional copies of the prostate cancer risk allele resulted in lower beta-MSP but higher PSA levels, and singly explained 23% and 5% of the variation seen in semen beta-MSP and PSA, respectively. Additional SNPs at MSMB are associated with beta-MSP and PSA independently of rs10993994.
CONCLUSIONS: SNPs at MSMB correlate with physiologic variation in beta-MSP and PSA levels in the blood and semen of healthy young Swedish men. In particular, rs10993994 has a strong effect on beta-MSP levels. IMPACT: Our results suggest a mechanism by which rs10993994 might predispose to prostate cancer and raise the possibility that genetic variation might need to be considered in interpreting the levels of these biomarkers. (c)2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20696662      PMCID: PMC2946372          DOI: 10.1158/1055-9965.EPI-10-0431

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  30 in total

1.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

2.  WHAP: haplotype-based association analysis.

Authors:  Shaun Purcell; Mark J Daly; Pak C Sham
Journal:  Bioinformatics       Date:  2006-11-21       Impact factor: 6.937

3.  PLINK: a tool set for whole-genome association and population-based linkage analyses.

Authors:  Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham
Journal:  Am J Hum Genet       Date:  2007-07-25       Impact factor: 11.025

4.  Cellular expression of beta-microseminoprotein (beta-MSP) mRNA and its protein in untreated prostate cancer.

Authors:  T Tsurusaki; T Koji; H Sakai; H Kanetake; P K Nakane; Y Saito
Journal:  Prostate       Date:  1998-05       Impact factor: 4.104

5.  Strong bias in the location of functional promoter polymorphisms.

Authors:  Paul R Buckland; Bastiaan Hoogendoorn; Sharon L Coleman; Carol A Guy; S Kaye Smith; Michael C O'Donovan
Journal:  Hum Mutat       Date:  2005-09       Impact factor: 4.878

6.  Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age.

Authors:  Charlotta Sävblom; Johan Malm; Aleksander Giwercman; Jan-Ake Nilsson; Göran Berglund; Hans Lilja
Journal:  Prostate       Date:  2005-09-15       Impact factor: 4.104

7.  Beta microseminoprotein is not a prostate-specific protein. Its identification in mucous glands and secretions.

Authors:  H Weiber; C Andersson; A Murne; G Rannevik; C Lindström; H Lilja; P Fernlund
Journal:  Am J Pathol       Date:  1990-09       Impact factor: 4.307

8.  Molecular cloning of a small prostate protein, known as beta-microsemenoprotein, PSP94 or beta-inhibin, and demonstration of transcripts in non-genital tissues.

Authors:  M Ulvsbäck; C Lindström; H Weiber; P A Abrahamsson; H Lilja; A Lundwall
Journal:  Biochem Biophys Res Commun       Date:  1989-11-15       Impact factor: 3.575

9.  Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis.

Authors:  S V Garde; V S Basrur; L Li; M A Finkelman; A Krishan; L Wellham; E Ben-Josef; M Haddad; J D Taylor; A T Porter; D G Tang
Journal:  Prostate       Date:  1999-02-01       Impact factor: 4.104

10.  A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis.

Authors:  Robert K Nam; Jonathan R Reeves; Ants Toi; Helene Dulude; John Trachtenberg; Marjan Emami; Luc Daigneault; Chandra Panchal; Linda Sugar; Michael A S Jewett; Steven A Narod
Journal:  J Urol       Date:  2006-04       Impact factor: 7.450

View more
  17 in total

1.  Variants at IRX4 as prostate cancer expression quantitative trait loci.

Authors:  Xing Xu; Wasay M Hussain; Joseph Vijai; Kenneth Offit; Mark A Rubin; Francesca Demichelis; Robert J Klein
Journal:  Eur J Hum Genet       Date:  2013-09-11       Impact factor: 4.246

2.  Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.

Authors:  Robert J Klein; Christer Hallden; Amit Gupta; Caroline J Savage; Anders Dahlin; Anders Bjartell; Jonas Manjer; Peter T Scardino; David Ulmert; Peter Wallström; Andrew J Vickers; Hans Lilja
Journal:  Eur Urol       Date:  2011-11-07       Impact factor: 20.096

3.  Genetic correction of PSA values using sequence variants associated with PSA levels.

Authors:  Julius Gudmundsson; Soren Besenbacher; Patrick Sulem; Daniel F Gudbjartsson; Isleifur Olafsson; Sturla Arinbjarnarson; Bjarni A Agnarsson; Kristrun R Benediktsdottir; Helgi J Isaksson; Jelena P Kostic; Sigurjon A Gudjonsson; Simon N Stacey; Arnaldur Gylfason; Asgeir Sigurdsson; Hilma Holm; Unnur S Bjornsdottir; Gudmundur I Eyjolfsson; Sebastian Navarrete; Fernando Fuertes; Maria D Garcia-Prats; Eduardo Polo; Ionel A Checherita; Mariana Jinga; Paula Badea; Katja K Aben; Jack A Schalken; Inge M van Oort; Fred C Sweep; Brian T Helfand; Michael Davis; Jenny L Donovan; Freddie C Hamdy; Kristleifur Kristjansson; Jeffrey R Gulcher; Gisli Masson; Augustine Kong; William J Catalona; Jose I Mayordomo; Gudmundur Geirsson; Gudmundur V Einarsson; Rosa B Barkardottir; Eirikur Jonsson; Viorel Jinga; Dana Mates; Lambertus A Kiemeney; David E Neal; Unnur Thorsteinsdottir; Thorunn Rafnar; Kari Stefansson
Journal:  Sci Transl Med       Date:  2010-12-15       Impact factor: 17.956

4.  Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB.

Authors:  Mesude Bicak; Xing Wang; Xiaoni Gao; Xing Xu; Riina-Minna Väänänen; Pekka Taimen; Hans Lilja; Kim Pettersson; Robert J Klein
Journal:  Hum Mol Genet       Date:  2020-06-27       Impact factor: 6.150

Review 5.  MSMB variation and prostate cancer risk: clues towards a possible fungal etiology.

Authors:  Siobhan Sutcliffe; Angelo M De Marzo; Karen S Sfanos; Martin Laurence
Journal:  Prostate       Date:  2014-01-24       Impact factor: 4.104

6.  Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations.

Authors:  Christopher A Haiman; Daniel O Stram; Andrew J Vickers; Lynne R Wilkens; Katharina Braun; Camilla Valtonen-André; Mari Peltola; Kim Pettersson; Kevin M Waters; Loic Le Marchand; Laurence N Kolonel; Brian E Henderson; Hans Lilja
Journal:  J Natl Cancer Inst       Date:  2012-12-03       Impact factor: 13.506

7.  Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer.

Authors:  Bao-Li Chang; Lucinda Hughes; David Y T Chen; Laura Gross; Karen Ruth; Veda N Giri
Journal:  BJU Int       Date:  2013-08-13       Impact factor: 5.588

8.  Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men.

Authors:  Charlotta Sävblom; Christer Halldén; Angel M Cronin; Torbjörn Säll; Caroline Savage; Emily A Vertosick; Robert J Klein; Aleksander Giwercman; Hans Lilja
Journal:  Clin Chem       Date:  2013-11-22       Impact factor: 8.327

9.  Validation of prostate cancer risk variants rs10993994 and rs7098889 by CRISPR/Cas9 mediated genome editing.

Authors:  Xing Wang; James E Hayes; Xing Xu; Xiaoni Gao; Dipti Mehta; Hans G Lilja; Robert J Klein
Journal:  Gene       Date:  2020-10-26       Impact factor: 3.688

10.  The rs10993994 in the proximal MSMB promoter region is a functional polymorphism in Asian Indian subjects.

Authors:  Deepa R Mhatre; Smita D Mahale; Mohammed I Khatkhatay; Swati K Achrekar; Swapna S Desai; Dhanashree D Jagtap; Jayesh V Dhabalia; Hemant B Tongaonkar; Sucheta P Dandekar; Anand M Varadkar
Journal:  Springerplus       Date:  2015-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.